1. Iwamoto M, Kawada K, Nakamoto Y, Itatani Y, Inamoto S, Toda K, Kimura H, Sasazuki T, Shirasawa S, Okuyama H, Inoue M, Hasegawa S, Togashi K, Sakai Y. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med, 55(12):2038-2044, 2014
2. Sun Q, Luo T, Ren Y, Florey O, Shirasawa S, Sasazuki T, Robinson DN, Overholtzer M. Competition between human cells by entosis. Cell Res, 24(11):1299-1310, 2014
3. Tanaka Y, Kulkeaw K, Inoue T, Tan KS, Nakanishi Y, Shirasawa S, Sugiyama D. Dok2 likely down-regulates Klf1 in mouse erythroleukemia cells. Anticancer Res, 34(8): 4561-4567, 2014
4. Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y, Shirasawa S. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer Res, 34(8): 4551-4555, 2014
5. Doi K, Ishikura S, Shirasawa S. The roles of ZFAT in thymocyte differentiation and homeostasis of peripheral naive T-cells. Anticancer Res, 34(8):4489-4495, 2014
6. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep, 7(6):1940-1955, 2014
7. Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC. Adrenomedullin is a therapeutic target in colorectal cancer. Int J Cancer, 134(9):2041-2050, 2014
8. Organ SL, Hai J, Radulovich N, Marshall CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M, Tsao MS. p120RasGAP is a mediator of Rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell Line. PLoS ONE, 9(1):e86103, 2014
9. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer, 134(9):2146-2155, 2014
2. Sun Q, Luo T, Ren Y, Florey O, Shirasawa S, Sasazuki T, Robinson DN, Overholtzer M. Competition between human cells by entosis. Cell Res, 24(11):1299-1310, 2014
3. Tanaka Y, Kulkeaw K, Inoue T, Tan KS, Nakanishi Y, Shirasawa S, Sugiyama D. Dok2 likely down-regulates Klf1 in mouse erythroleukemia cells. Anticancer Res, 34(8): 4561-4567, 2014
4. Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y, Shirasawa S. Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer Res, 34(8): 4551-4555, 2014
5. Doi K, Ishikura S, Shirasawa S. The roles of ZFAT in thymocyte differentiation and homeostasis of peripheral naive T-cells. Anticancer Res, 34(8):4489-4495, 2014
6. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep, 7(6):1940-1955, 2014
7. Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC. Adrenomedullin is a therapeutic target in colorectal cancer. Int J Cancer, 134(9):2041-2050, 2014
8. Organ SL, Hai J, Radulovich N, Marshall CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M, Tsao MS. p120RasGAP is a mediator of Rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell Line. PLoS ONE, 9(1):e86103, 2014
9. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer, 134(9):2146-2155, 2014